WO2004041303B1 - Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease - Google Patents

Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease

Info

Publication number
WO2004041303B1
WO2004041303B1 PCT/US2003/035199 US0335199W WO2004041303B1 WO 2004041303 B1 WO2004041303 B1 WO 2004041303B1 US 0335199 W US0335199 W US 0335199W WO 2004041303 B1 WO2004041303 B1 WO 2004041303B1
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum toxin
reflux disease
gastroesophageal reflux
oral formulation
peptic ulcers
Prior art date
Application number
PCT/US2003/035199
Other languages
French (fr)
Other versions
WO2004041303A1 (en
Inventor
Richard L Barron
Original Assignee
Allergan Inc
Richard L Barron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Richard L Barron filed Critical Allergan Inc
Priority to CA002504932A priority Critical patent/CA2504932A1/en
Priority to EP03778117A priority patent/EP1558279B1/en
Priority to AT03778117T priority patent/ATE454162T1/en
Priority to AU2003286901A priority patent/AU2003286901B2/en
Priority to DE60330889T priority patent/DE60330889D1/en
Priority to DK03778117.6T priority patent/DK1558279T3/en
Priority to BR0315979-5A priority patent/BR0315979A/en
Priority to NZ539170A priority patent/NZ539170A/en
Priority to MXPA05004629A priority patent/MXPA05004629A/en
Priority to JP2004550494A priority patent/JP4808404B2/en
Publication of WO2004041303A1 publication Critical patent/WO2004041303A1/en
Publication of WO2004041303B1 publication Critical patent/WO2004041303B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Methods for treating peptic ulcers and methods for treating gastroesophageal reflux disease by oral administration of a botulinum toxin. Oral formulation of botulinum toxin A, B, C, D, E, F or G together with a carrier, e.g. flour, sugar, gelatin.

Claims

AMENDED CLAIMS[received by the International Bureau on 14 May 2004(14.05.2004); original claims 1-20 replaced by amended claims 1-6 (4 pages)]claim:
1. Use of a botulinum toxin for the manufacture of a medicament for treating a peptic ulcer.
2. the use of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.
3. The use of claim 1 wherein the peptic ulcer is a gastric ulcer.
4. The use of claim 1 wherein the peptic ulcer is a duodenal ulcer.
5. The use of claim 1 wherein the botulinum toxin is a botulinum toxin type A.
6. Use of a botulinum toxin for the manufacture of a medicament for treating a peptic ulcer or a gastroesophageal reflux disease by oral ingestion of the medicament.
47
PCT/US2003/035199 2002-11-05 2003-11-03 Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease WO2004041303A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002504932A CA2504932A1 (en) 2002-11-05 2003-11-03 Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease
EP03778117A EP1558279B1 (en) 2002-11-05 2003-11-03 Botulinum toxin for treating peptic ulcers and gastroesophageal reflux disease
AT03778117T ATE454162T1 (en) 2002-11-05 2003-11-03 BOTULINUM TOXIN FOR THE TREATMENT OF STOMACH ULCER AND GASTROESOPHAGEAL REFLUX
AU2003286901A AU2003286901B2 (en) 2002-11-05 2003-11-03 Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease
DE60330889T DE60330889D1 (en) 2002-11-05 2003-11-03 BOTULINUM TOXIN FOR THE TREATMENT OF STOMACH AND GASTROÖSOPHAGEAL REFLUX
DK03778117.6T DK1558279T3 (en) 2002-11-05 2003-11-03 Botulinum toxin for the treatment of ulcer peptic and gastroesophageal reflux disease
BR0315979-5A BR0315979A (en) 2002-11-05 2003-11-03 Oral formulation of botulinum toxin and use to treat peptic ulcers and gastroesophageal reflux disease
NZ539170A NZ539170A (en) 2002-11-05 2003-11-03 Oral formulation of botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease
MXPA05004629A MXPA05004629A (en) 2002-11-05 2003-11-03 Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease.
JP2004550494A JP4808404B2 (en) 2002-11-05 2003-11-03 Oral formulation of botulinum toxin and its use for treating peptic ulcer and gastroesophageal reflux disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/288,734 2002-11-05
US10/288,734 US7238357B2 (en) 2002-11-05 2002-11-05 Methods for treating ulcers and gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
WO2004041303A1 WO2004041303A1 (en) 2004-05-21
WO2004041303B1 true WO2004041303B1 (en) 2004-10-14

Family

ID=32175959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035199 WO2004041303A1 (en) 2002-11-05 2003-11-03 Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease

Country Status (15)

Country Link
US (1) US7238357B2 (en)
EP (1) EP1558279B1 (en)
JP (1) JP4808404B2 (en)
KR (1) KR101072179B1 (en)
CN (1) CN100349613C (en)
AT (1) ATE454162T1 (en)
AU (1) AU2003286901B2 (en)
BR (1) BR0315979A (en)
CA (1) CA2504932A1 (en)
DE (1) DE60330889D1 (en)
DK (1) DK1558279T3 (en)
ES (1) ES2337892T3 (en)
MX (1) MXPA05004629A (en)
NZ (1) NZ539170A (en)
WO (1) WO2004041303A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7844338B2 (en) * 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
JP5089388B2 (en) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド Degradable clostridial toxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
JP4491404B2 (en) * 2005-11-07 2010-06-30 住友電工ハードメタル株式会社 Tip changeable insert and tip changeable corner milling cutter
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080281365A1 (en) * 2007-05-09 2008-11-13 Tweden Katherine S Neural signal duty cycle
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
CN102014779B (en) 2008-05-09 2014-10-22 赫莱拉公司 Systems, assemblies, and methods for treating a bronchial tree
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8936471B2 (en) * 2009-02-15 2015-01-20 Cheryl L. Evans Flow rate measuring device
US9858831B2 (en) 2009-02-15 2018-01-02 Cheryl L. Evans Method for determining and prescribing quantifiable and customized diet for patient suffering from dysphagia
US8753124B2 (en) * 2009-02-15 2014-06-17 Cheryl Lynn Evans Method and apparatus for prescribing and preparing a reproducible and customized dysphagia diet
EP2480250B1 (en) 2009-09-24 2014-04-16 Allergan, Inc. Compositions comprising botulinum toxin A or B for use in the treatment of osteoporosis
CN112089394A (en) 2009-10-27 2020-12-18 努瓦拉公司 Delivery device with coolable energy emitting assembly
WO2011060200A1 (en) 2009-11-11 2011-05-19 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
ES2660901T3 (en) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compounds that inhibit neuronal exocytosis (II)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
PL3242884T3 (en) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN109790204A (en) 2016-09-29 2019-05-21 益普生生物制药有限公司 Heterozygosis neurotoxin
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023097181A1 (en) * 2021-11-23 2023-06-01 AEON Biopharma, Inc. Neurotoxin compositions for use in treating digestive disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
US5174468A (en) * 1991-01-30 1992-12-29 Holderman Lisa A Trash organizer
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
AU4646393A (en) 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69434610T2 (en) 1993-12-28 2008-11-27 Allergan, Inc., Irvine Use of the neurotoxic component of botulinum toxin for the treatment of muscle spasms
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (en) * 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． How to reduce headaches
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
ES2210273T5 (en) * 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. VIRUS WITH NEGATIVE CHAIN NON-SEGMENTED RECOMBINANT INFECTIVE.
US5571116A (en) * 1994-10-02 1996-11-05 United States Surgical Corporation Non-invasive treatment of gastroesophageal reflux disease
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6299839B1 (en) * 1995-08-31 2001-10-09 First Medical, Inc. System and methods for performing rotor assays
JP3506172B2 (en) * 1997-03-13 2004-03-15 信越半導体株式会社 Semiconductor wafer etching method
DK1475099T4 (en) * 1997-07-15 2014-05-19 Univ Colorado Use of botulinum toxin for the treatment of urinary incontinence
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
EP1586329A1 (en) 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
EP1334729A1 (en) 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2

Also Published As

Publication number Publication date
EP1558279B1 (en) 2010-01-06
WO2004041303A1 (en) 2004-05-21
AU2003286901A1 (en) 2004-06-07
NZ539170A (en) 2007-08-31
KR101072179B1 (en) 2011-10-10
CN1711103A (en) 2005-12-21
CN100349613C (en) 2007-11-21
DK1558279T3 (en) 2010-05-03
ATE454162T1 (en) 2010-01-15
KR20050084657A (en) 2005-08-26
US7238357B2 (en) 2007-07-03
CA2504932A1 (en) 2004-05-21
EP1558279A1 (en) 2005-08-03
BR0315979A (en) 2005-09-20
AU2003286901B2 (en) 2008-06-12
JP2006512316A (en) 2006-04-13
US20040086531A1 (en) 2004-05-06
JP4808404B2 (en) 2011-11-02
MXPA05004629A (en) 2005-06-08
DE60330889D1 (en) 2010-02-25
ES2337892T3 (en) 2010-04-30

Similar Documents

Publication Publication Date Title
WO2004041303B1 (en) Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease
JP2006512316A5 (en)
ATE142495T1 (en) USE OF RIFAXIMIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMIN FOR THE TREATMENT OF GASTIC DYSPEPSIA CAUSED BY HELICOBACTER PYLORI
EP0130779A3 (en) Pharmaceutical composition suitable for intestinal administration
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
CA2117490A1 (en) Purified vacuolating toxin from helicobacter pylori and methods to use same
AU6357596A (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
AU2705588A (en) New ciclosporin crystal form, processes for its production, pharmaceutical compositions containing it and its use.
CA2289979A1 (en) Methods of modulating immune coagulation
DE69927584D1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF STOMACH DISEASES
DE69620582T2 (en) Use of bismuth compounds in the manufacture of a medicament for the treatment of upset stomach caused by Helicobacter pylori
DE3771882D1 (en) GLYCOPEPTIDE ANTIBIOTICS, THEIR PRODUCTION AND USE, AND MICROORGANISMS THAT MANUFACTURE THEM.
CA2017339A1 (en) Stabilized spore-forming viable microorganisms preparation, its production pellet thereof
EP0206807A3 (en) Novel amino acid derivatives
CA2353048A1 (en) Pharmaceutical composition useful in the prevention or treatment of peptic ulcers
EP1145644A3 (en) Glycoprotein having inhibitory activity against helicobacter pylori colonization
Centers for Disease Control and Prevention (CDC Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis
CA2089748A1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
AU1192397A (en) Substituted thiazolines and their use for controlling animal pests
WO1998043649A3 (en) Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
WO2001077685A3 (en) Diagnosis and treatment of gastrointestinal disease
HRP950271A2 (en) New peptide active substance and the production thereof
WO2002062944A2 (en) Novel physiologically active peptide and use thereof
CA2261041A1 (en) Bacillus thuringiensis strains showing improved production of certain lepidopteran-toxic crystal proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20040514

WWE Wipo information: entry into national phase

Ref document number: 539170

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003286901

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003778117

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 651/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004629

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057007895

Country of ref document: KR

Ref document number: 2504932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004550494

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038A27980

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003778117

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057007895

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0315979

Country of ref document: BR